Teleflex Reports Strong Q3 2025 Financial Results

Teleflex ( (TFX) ) has issued an announcement.

Teleflex announced its financial results for the third quarter ending September 28, 2025, reporting a 19.4% increase in GAAP revenue compared to the previous year. Despite a decrease in order rates for its intra-aortic balloon pump portfolio, the company exceeded expectations in adjusted operating margin and earnings per share. Teleflex is also narrowing its revenue growth guidance for 2025 and continues to focus on its strategy to drive shareholder value, including the potential sale of its NewCo division.

The most recent analyst rating on (TFX) stock is a Buy with a $132.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.

Spark’s Take on TFX Stock

According to Spark, TipRanks’ AI Analyst, TFX is a Outperform.

Teleflex’s overall stock score is driven by strong financial performance and positive earnings call highlights, including strategic acquisitions and exceeding guidance. Technical analysis and valuation present some concerns, with the stock trading below its 200-day moving average and a high P/E ratio suggesting potential overvaluation. Despite these challenges, the company’s robust financial health and strategic initiatives support a positive outlook.

To see Spark’s full report on TFX stock, click here.

More about Teleflex

Teleflex Incorporated is a company operating in the medical technology industry, focusing on providing products and services related to vascular access, interventional procedures, anesthesia, surgical, and interventional urology. The company is engaged in advancing its value creation strategy and is in the process of separating into two companies, RemainCo and NewCo, with a potential sale of NewCo being a primary focus.

Average Trading Volume: 558,098

Technical Sentiment Signal: Sell

Current Market Cap: $5.5B

For an in-depth examination of TFX stock, go to TipRanks’ Overview page.